{"filing":{"accession_number":"0001493152-26-039488","cik":"0001583771","ticker":"CTRVP","company_name":"Hepion Pharmaceuticals, Inc.","form":"8-K","filing_date":"2026-08-20","report_date":"2026-08-19","primary_document":"form8-k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1583771/000149315226039488/form8-k.htm"},"events":[{"id":28927,"run_id":26472,"accession_number":"0001493152-26-039488","anchor_item_number":"5.02","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"summary":"The Board of Directors approved the appointment of James Liddy as a director of the Company, effective immediately on August 19, 2026. This is a clear director appointment disclosed under Item 5.02, which is material to investors as board composition affects governance and oversight. The filing explicitly states there are no conflicting arrangements or related-party transactions, indicating a straightforward appointment event.","company_name":"Hepion Pharmaceuticals, Inc.","ticker":"CTRVP","filing_date":"2026-08-20","form":"8-K","submitted_at":null,"items":[{"id":31023,"accession_number":"0001493152-26-039488","item_number":"5.02","item_title":null,"event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The Board of Directors approved the appointment of James Liddy as a director of the Company, effective immediately on August 19, 2026. This is a clear director appointment disclosed under Item 5.02, which is material to investors as board composition affects governance and oversight. The filing explicitly states there are no conflicting arrangements or related-party transactions, indicating a straightforward appointment event.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-20T20:46:38.891472+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":31023,"accession_number":"0001493152-26-039488","item_number":"5.02","item_title":null,"event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The Board of Directors approved the appointment of James Liddy as a director of the Company, effective immediately on August 19, 2026. This is a clear director appointment disclosed under Item 5.02, which is material to investors as board composition affects governance and oversight. The filing explicitly states there are no conflicting arrangements or related-party transactions, indicating a straightforward appointment event.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-20T20:46:38.891472+00:00","company_name":"Hepion Pharmaceuticals, Inc.","ticker":"CTRVP","filing_date":"2026-08-20"}]}